Global Transient Ischemic Attack Market is expected to grow at a CAGR of 6.16% during the forecast period from 2018-2025

A new research report published by Fior Markets with the title Global Transient Ischemic Attack Market by Diagnosis (CT Scan, Magnetic Resonance Imaging, Others), Treatment, End User, Regions, and Global Forecast 2018-2025.

As per the report, the global transient ischemic attack market is expected to grow from USD 1529.41 Million in 2017 to USD 2467.82 Million by 2025, at a CAGR of 6.16% during the forecast period from 2018-2025. North America region emerged as the leader in global transient ischemic attack market with a 38.40% share of market revenue in 2017. Whereas Asia Pacific region is expected to grow at an accelerated CAGR of 8.62% over the forecasted period.

DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/375994/request-sample

Major players in the global transient ischemic attack market are Koninklijke Philips N.V., Stryker Corporation, Johnson & Johnson Services Inc., Boston Scientific Corporation, Sanofi SA, Bayer AG, Pfizer Inc., Siemens AG, F. Hoffmann-La Roche AG, GE Healthcare, Penumbra, Inc., Medtronic PLC, Abbott Laboratories, Merck & Co., Inc., and Boehringer Ingelheim GmbH, LivaNova PLC, Cyberonics, Inc, NeuroMetrix, Inc. among others. Combination of drugs are being increasingly preferred as the first line of action for treating the transient ischemic attack. For instance the study undertaken by the University of Texas at Austin shows that taking low-dose aspirin along with the clot-preventing drug Plavix (clopidogrel) after such events appeared to reduce the risk of major stroke over the next 90 days.

Diagnosis segment is divided into computed tomography (CT) scan, carotid duplex scanning, magnetic resonance Imaging and echocardiography. On account of it’s to better suitability and better imaging quality magnetic resonance imaging (MRI) segment led the global transient ischemic attack market with a 56.29% share of revenue in 2017. Treatment is segmented into drugs and surgery. Drugs are the primary line of treatment against the transient ischemic attack. Thus drugs segment led the global transient ischemic attack market with a 62.78% share of revenue in 2017. On account of high procedure efficiency of minimally invasive surgeries coupled with their benefits such as faster recovery and less post-surgical pain, surgery segment is projected to progress at a healthy pace over the forecast period. End user segment is categorized into hospitals and clinics, diagnostic centers and research laboratories. Precise and timely diagnosis is the most important phase for deciding the most effective line of cure for the treatment of transient ischemic attack. Thus diagnostic centers and research laboratories segment and emerged as a leader with a 42.86% share of revenue in 2017. Growing number of private hospitals and clinics are projected to boost hospitals and clinics segment to grow at a CAGR of 8.78% over the forecast period.

Even though growing prevalence of neurological disorders and increase in global geriatric population are driving the global transient ischemic attack market, lack of skilled physicians and surgeons and growing treatment and hospitalization expenses are anticipated to dampen the market growth.

ACCESS FULL REPORT: https://www.fiormarkets.com/report/global-transient-ischemic-attack-market-by-diagnosis-ct-375994.html

About the report: 
The global transient ischemic attack market is analysed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on sales@fiormarkets.com or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211
Email: sales@fiormarkets.com
Web: www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.